glp 1 agonists drugs Holding GLP-1 Prior to Elective Procedures Semaglutide vs. Other GLP-1 Receptor

Rhode Island's Medicaid agency proposes ending GLP-1 coverage for weight loss while keeping diabetes uses, citing soaring costs.

Two major ongoing trials are likely to change that, with potentially big implications for clinical practice.

This analysis was part of the IMI-Stratification of Obesity Phenotypes to Optimize Future Obesity Therapy (IMI-SOPHIA) project

Exposures Two cohorts were assembled, with the first composed of patients who started and continued on GLP-1 receptor agonists or DPP-4 inhibitors between 1 January 2007 and 31 December 2020 and the second composed of patients who started and continued on GLP-1 receptor agonists or SGLT-2 inhibitors between 1 January 1 2013 and 31 December 2020